Literature DB >> 16731924

The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.

Alexander Bukreyev1, Maria Elina Serra, Federico R Laham, Guillermina A Melendi, Steven R Kleeberger, Peter L Collins, Fernando P Polack.   

Abstract

The cytotoxic T-lymphocyte (CTL) response is important for the control of viral replication during respiratory syncytial virus (RSV) infection. The attachment glycoprotein (G) of RSV does not encode major histocompatibility complex class I-restricted epitopes in BALB/c mice (H-2(d)). Furthermore, studies to date have described an absence of significant CTL activity directed against this protein in humans. Therefore, G previously was not considered necessary for the generation of RSV-specific CTL responses. In this study, we demonstrate that, despite lacking H-2(d)-restricted epitopes, G enhances the generation of an effective CTL response against RSV. Furthermore, we show that this stimulatory effect is independent of virus titers and RSV-induced inflammation; that it is associated primarily with the secreted form of G; and that the effect depends on the cysteine-rich region of G (GCRR), a segment conserved in wild-type isolates worldwide. These findings reveal a novel function for the GCRR with potential implications for the generation of protective cellular responses and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16731924      PMCID: PMC1472564          DOI: 10.1128/JVI.02671-05

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection.

Authors:  P J Openshaw; K Anderson; G W Wertz; B A Askonas
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein.

Authors:  N Elango; G A Prince; B R Murphy; S Venkatesan; R M Chanock; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

4.  Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.

Authors:  Jun Guo; Minghui Zhang; Baocheng Wang; Zhenglong Yuan; Zhenhong Guo; Taoyong Chen; Yizhi Yu; Zhihai Qin; Xuetao Cao
Journal:  Int J Cancer       Date:  2003-01-10       Impact factor: 7.396

5.  Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells.

Authors:  S M Varga; X Wang; R M Welsh; T J Braciale
Journal:  Immunity       Date:  2001-10       Impact factor: 31.745

6.  The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.

Authors:  S M Varga; E L Wissinger; T J Braciale
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

7.  Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus.

Authors:  John A Rutigliano; Michael T Rock; Amanda K Johnson; James E Crowe; Barney S Graham
Journal:  Virology       Date:  2005-07-05       Impact factor: 3.616

8.  Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.

Authors:  Y W Tang; B S Graham
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Virus clearance and immunopathology by CD8(+) T cells during infection with respiratory syncytial virus are mediated by IFN-gamma.

Authors:  Tobias Ostler; Wendy Davidson; Stephan Ehl
Journal:  Eur J Immunol       Date:  2002-08       Impact factor: 5.532

10.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

View more
  18 in total

1.  Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.

Authors:  Guillermina A Melendi; Fidel Zavala; Ursula J Buchholz; Guy Boivin; Peter L Collins; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

Review 2.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

3.  Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses.

Authors:  Guillermina A Melendi; Dowd Bridget; Ana C Monsalvo; Federico F Laham; Patricio Acosta; Maria Florencia Delgado; Fernando P Polack; Pablo M Irusta
Journal:  Virus Genes       Date:  2010-11-04       Impact factor: 2.332

4.  Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.

Authors:  S Boyoglu-Barnum; S O Todd; J Meng; T R Barnum; T Chirkova; L M Haynes; S J Jadhao; R A Tripp; A G Oomens; M L Moore; L J Anderson
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

5.  A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Kelsey A Gaston; Sean O Todd; Cemil Boyoglu; Tatiana Chirkova; Thomas R Barnum; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

6.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

7.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

8.  An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats.

Authors:  Hoyin Mok; Sharon J Tollefson; Amy B Podsiad; Bryan E Shepherd; Vasiliy V Polosukhin; Robert E Johnston; John V Williams; James E Crowe
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

9.  Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic.

Authors:  Toby M Ward; Vicki Traina-Dorge; Kara A Davis; Wayne L Gray
Journal:  J Gen Virol       Date:  2008-03       Impact factor: 3.891

10.  Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection.

Authors:  Jae-Rang Yu; Sol Kim; Jee-Boong Lee; Jun Chang
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.